Insmed price target raised to $22 from $13 at Leerink

Leerink raised its fair value estimate for Insmed shares to $22 citing increased conviction that the company's Arikace drug is poised to be become a first-in-line treatment for non-tuberculous mycobacteria infections. The firm believes non-tuberculous mycobacteria could be a bigger market opportunity than cystic fibrosis and keeps an Outperform rating on the stock.

View Comments (0)